The Kentucky report is the latest to examine a controversial practice known as spread pricing, in which PBMs pay drugstores one price for a treatment while charging another to clients.

Plaintiffs contend companies are illegally raising insulin prices to provide rebates for pharmacy-benefit managers who decide which drugs get on preferred insurance lists.

The measure, released by HHS on Thursday, would roll back so-called safe-harbor protections for drug rebates.

According to an new analysis, drug markups by PBMs in New York more than doubled from 2016 to 2017.

The two companies disagreed over prescription reimbursement rates and what Walmart referred to as the "unregulated power" of PBMs.

The Health Transformation Alliance, a coalition of more than 40 big companies, will use a new online tool to get better deals on their medications.

Partnerships “enable us to quickly align our products, services and people to the needs of the rapidly changing and integrated omnichannel marketplace,” says CEO Stefano Pessina.

The path is clear for a merger that will create a health-care giant with a hand in insurance, prescription-drug benefits and drugstores.